Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets
Our findings proposed biomarkers with prognostic potential, laying the groundwork for future in vitro validation and therapeutic exploration. This contributes to a deeper understanding of the genes associated with bladder TME and may improve prognostic precision in BLCA management.
Authors
- Laura Bukavina (ORCID: https://orcid.org/0000-0001-7129-6230)
- Daniel Ranti (ORCID: https://orcid.org/0000-0002-8310-1063)
- John P. Sfakianos (ORCID: https://orcid.org/0000-0002-3101-0266)
- Philip H. Abbosh (ORCID: https://orcid.org/0000-0003-3611-9532)
- Imran Safder (ORCID: https://orcid.org/0000-0002-9547-2531)
- Shilpa Gupta (ORCID: https://orcid.org/0000-0002-8775-503X)
- Nicole Uzzo
- Henkel Valentine (ORCID: https://orcid.org/0000-0001-6869-3497)
- Elizabeth R. Plimack (ORCID: https://orcid.org/0000-0002-7618-0744)
- Robert G. Uzzo (ORCID: https://orcid.org/0000-0003-2398-6530)
- Jason Robert Brown (ORCID: https://orcid.org/0000-0001-6225-7555)
- Alexander Kutikov (ORCID: https://orcid.org/0000-0003-1525-6247)
- Christopher Weight (ORCID: https://orcid.org/0000-0001-9381-959X)
- George Haber
Institutions
- Fox Chase Cancer Center (US)
- Cleveland Clinic (US)
- University Hospitals of Cleveland (US)
- Jefferson Einstein Philadelphia Hospital (US)
- Mount Sinai Medical Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/po.23.00661
- Citations
- 5
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Cisco Systems
- Gilead Sciences
- Regeneron Pharmaceuticals
- Exelixis
- Adaptive Biotechnologies
- Moderna
- Seagen
- Natera
- Eisai
- Astellas Pharma
- Genentech
- EMD Serono
- Foundation Medicine